The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Shikh E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Rebrova E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ryazanova A.Y.

Volgograd State Medical University

Panteleeva L.R.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Arzhimatova G.Sh.

Russian Medical Academy of Continuing Professional Education;
S.P. Botkin City Clinical Hospital

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Drug-induced uveitis

Authors:

Ostroumova O.D., Shikh E.V., Rebrova E.V., Ryazanova A.Y., Panteleeva L.R., Arzhimatova G.Sh., Moshetova L.K.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(1): 94‑101

DOI: 10.17116/oftalma202113701194

Views: 3692

Downloaded: 127

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Ostroumova OD, Shikh EV, Rebrova EV, Ryazanova AY, Panteleeva LR, Arzhimatova GSh, Moshetova LK. Drug-induced uveitis. Russian Annals of Ophthalmology. 2021;137(1):94‑101. (In Russ.)
https://doi.org/10.17116/oftalma202113701194

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Close metadata

In recent years, an increasing amount of attention has been paid to medicinal products as possible risk factors in the development of eye diseases. The frequency of diagnosed drug-induced uveitis is growing yearly, which can be attributed to the appearance of new drugs — biological agents (immune checkpoint inhibitors, BRAF and MEK inhibitors, vascular endothelial growth factor inhibitors, tumor necrosis factor-α inhibitors), as well as systemic bisphosphonates and some antiviral drugs. The time interval between the beginning of the drug use and the appearance of uveitis symptoms varies from several days to months. Common symptoms include eye pain, photophobia, the appearance of floating opacities, and reduced vision associated with active inflammatory changes in the retina and optic nerve and outcomes of those inflammations. Timely diagnosis, cancellation of the drug that caused uveitis and appointment of adequate anti-inflammatory therapy in most cases effectively stops the symptoms of the disease, which determines the relevance of attention to the prevalence, pathogenesis, diagnosis and treatment of drug-induced uveitis.

Keywords:

uveitis
drug-induced uveitis
adverse drug reactions

Authors:

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Shikh E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Rebrova E.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Ryazanova A.Y.

Volgograd State Medical University

Panteleeva L.R.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Arzhimatova G.Sh.

Russian Medical Academy of Continuing Professional Education;
S.P. Botkin City Clinical Hospital

Moshetova L.K.

Russian Medical Academy of Continuing Professional Education

Received:

02.06.2020

Accepted:

01.09.2020

List of references:

  1. Moorthy RS, Moorthy MS, Cunningham ETJr. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29(6):588-603.  https://doi.org/10.1097/ICU.0000000000000530
  2. Oftal’mologiya. Natsional’noye rukovodstvo [Ophthalmology. National guidelance]. Eds Avetisov S.E., Egorov E.A., Moshetova L.K., Neroev V.V., Takhchidi H.P. M.: GEOTAR-Media; 2018. (In Russ.).
  3. Cordero-Coma M, Salazar-Méndez R, Garzo-García I, Yilmaz T. Drug-induced uveitis. Expert Opin Drug Saf. 2015;14(1):111-126.  https://doi.org/10.1517/14740338.2015.972363
  4. Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf. 1997;17(3):197-207.  https://doi.org/10.2165/00002018-199717030-00005
  5. Prescription Drug Information, Interactioms, Side Effects. Accessed May 5, 2020. https://www.drugs.com
  6. Shifera AS, Kopplin L, Lin P, Suhler EB. Drug-induced Uveitis. International Ophthalmol Clin. 2015;55(2):47-65.  https://doi.org/10.1097/IIO.0000000000000059
  7. Ermakova NA. Classification and clinical evaluation of uveitis. RMZH Klinicheskaya oftal’mologiya. 2003;4:146. (In Russ.).
  8. Ambati J, Wynne K, Angerame M, Robinson M. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. 1999;83(10):1153-1158. https://doi.org/10.1136/bjo.83.10.1153
  9. Knape RM, Sayyad FE, Davis JL. Moxifloxacin and bilateral acute iris transillumination. J Ophthalmic Inflamm Infect. 2013;3(10):1-3.  https://doi.org/10.1186/1869-5760-3-10
  10. Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):187-191.  https://doi.org/10.1007/s00417-01738352
  11. Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6(1):14.  https://doi.org/10.1186/s12348-016-0082-3
  12. Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2017;44(8):975-976.  https://doi.org/10.1111/1346-8138.13612
  13. Kanno H, Ishida K, Yamada W, Nishida T, Takahashi N, Mochizuki K, Mizuno Y, Matsuyama K, Takahashi T, Seishima M. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J Infect Chemother. 2017;23(11):774-777.  https://doi.org/10.1016/j.jiac.2017.04.007
  14. Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5(5):694-700.  https://doi.org/10.1002/ccr3.911
  15. Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A, Tanaka H, Furudate S, Hashimoto A, Aiba S. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735-737.  https://doi.org/10.1111/1346-8138.14273
  16. Tan AX, Ang A, Campbell WG, Fabinyi DC. Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma. Clin Exp Ophthalmol. 2018;46(7):819-821.  https://doi.org/10.1111/ceo.13197
  17. Karlin J, Gentzler R, Golen J. Bilateral Anterior Uveitis Associated with Nivolumab Therapy. Ocul Immunol Inflamm. 2018;26(2):283-285.  https://doi.org/10.1080/09273948.2016.1215473
  18. Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother. 2015;38(2):80-84.  https://doi.org/10.1097/CJI.0000000000000066
  19. Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319-322.  https://doi.org/10.1016/j.joco.2019.05.002
  20. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063-1078. https://doi.org/10.1097/IAE.0000000000002181
  21. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831-837.e2.  https://doi.org/10.1016/j.ajo.2014.07.003
  22. Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental melanin-protein induced uveitis (EMIU) is the sole type of uveitis evoked by a diversity of ocular melanin preparations and melanin-derived soluble polypeptides. Jpn J Ophthalmol. 1996;40(4):459-468. 
  23. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122-136.  https://doi.org/10.1177/1758834014566428
  24. Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalm Inflamm Infect. 2015;5(17):1-3.  https://doi.org/10.1186/s12348-015-0049-9
  25. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. AIDS. 2000; 14(11):1571-1581.
  26. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol. 1997;115(6):733-737.  https://doi.org/10.1001/archopht.1997.01100150735008
  27. Chavez-de la Paz E, Arevalo JF, Kirsch LS, Munguia D, Rahhal FM, De Clercq E, Freeman WR. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology. 1997;104:539-544. 
  28. Akler ME, Johnson DW, Burman WJ, Johnson SC. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105(4):651-657.  https://doi.org/10.1016/S0161-6420(98)94019-2
  29. Shafran DS, Singer J, Zarowny DP, Deschênes J, Phillips P, Turgeon F, Aoki FY, Toma E, Miller M, Raymond Duperval R, Lemieux C, Walter F. Determinants of Rifabutin-Associated Uveitis in Patients Treated with Rifabutin, Clarithromycin, and Ethambutol for Mycobacterium avium Complex Bacteremia: A Multivariate Analysis. J Infect Dis. 1998;177(1):252-255.  https://doi.org/10.1086/517366
  30. Smith WM, Reddy MG, Hutcheson KA, Bishop RJ, Sen HN. Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalm Inflammat Infect. 2012;2:149-152.  https://doi.org/10.1007/s12348-012-0059-9
  31. Skolik S, Willermain F, Caspers LE. Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm. 2005; 13(6):483-485.  https://doi.org/10.1080/09273940590951115
  32. Kuper JI, D’Aprile M. Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000;39(3):203-214.  https://doi.org/10.2165/00003088-200039030-00003
  33. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998;63(4):414-421. 
  34. Jacobs DS, Piliero PJ, Kuperwaser MG, Smith JA, Harris SD, Flanigan TP, Goldberg JH, Ives DV. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol. 1994; 118(6):716-722.  https://doi.org/10.1016/S0002-9394(14)72550-4
  35. Tilden ME, Rosenbaum JT, Fraunfelder FT. Systemic sulfonamides as a cause of bilateral, anterior uveitis. Arch Ophthalmol. 1991;109(1):67-69.  https://doi.org/10.1001/archopht.1991.01080010069035
  36. Fraunfelder FW, Winthrop K, Suhler E, Choi D, Fraunfelder FT. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2009;29(2):285-286.  https://doi.org/10.1097/IAE.0b013e318191df82
  37. French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008; 28(6):889-893.  https://doi.org/10.1097/IAE.0b013e31816576ef
  38. Umunakwe OC, Herren D, Kim SJ, Kohanim S. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Digit J Ophthalmol. 2017;23(4):18-21.  https://doi.org/10.5693/djo.02.2017.08.002
  39. Peterson JD, Bedrossian EH. Bisphosphonate-associated orbital inflammation — a case report and review. Orbit. 2012;31(2):119-123.  https://doi.org/10.3109/01676830.2011.648818
  40. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. https://doi.org/10.1056/NEJMoa067312
  41. Butler NJ, Suhler EB. Levofloxacin-Associated Panuveitis With Chorioretinal Lesions. Arch Ophthalmol. 2012;130(10):1342-1344. https://doi.org/10.1001/archophthalmol.2012.2260
  42. Tugal-Tutkun I, Araz B, Taskapili M, Akova YA, Yalniz-Akkaya Z, Berker N, Emre S, Gezer A. Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. Ophthalmology. 2009;116(8): 1552-1557. https://doi.org/10.1016/j.ophtha.2009.02.019
  43. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187-1193. https://doi.org/10.1016/s0140-6736(02)08215-6
  44. Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J; Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883-886.  https://doi.org/10.1093/rheumatology/kep046
  45. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188-193.  https://doi.org/10.1016/j.autrev.2009.10.003
  46. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248-3252. https://doi.org/10.1002/art.22918
  47. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena MBS. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina. 2006; 26(7):841-842.  https://doi.org/10.1097/01.iae.0000234629.22614.cd
  48. Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC, Syed NA, Russell SR. Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surg Lasers Imaging. 2011;42(4):292-296.  https://doi.org/10.3928/15428877-20110603-04
  49. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after antivascular endothelial growth factor therapy in Medicare patients with agerelated macular degeneration. Am J Ophthalmol. 2011;152(2):266-272.  https://doi.org/10.1016/j.ajo.2011.01.053
  50. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
  51. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908. https://doi.org/10.1056/NEJMoa1102673
  52. Hahn P, Chung MM, Flynn HW Jr, Huang SS, Kim JE, Mahmoud TH, Sadda SR, Dugel PU. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA Ophthalmol. 2015;133(4):421-426.  https://doi.org/10.1001/jamaophthalmol.2014.5650
  53. Khanani AM, Cohen GL, Zawadzki R. A Prospective Masked Clinical Assessment of Inflammation after Intravitreal Injection of Ranibizumab or Aflibercept. J Ocul Pharmacol Ther. 2016;32(4):216-218.  https://doi.org/10.1089/jop.2015.0152
  54. Grewal DS, Schwartz T, Fekrat S. Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48(5):428-431.  https://doi.org/10.3928/23258160-20170428-10
  55. Scott IU, Ip MS, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128. https://doi.org/10.1001/archophthalmol.2009.233
  56. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-1114. https://doi.org/10.1001/archophthalmol.2009.234
  57. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-1449. https://doi.org/10.1016/j.ophtha.2008.06.015
  58. Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm. 2005;13(4):295-300.  https://doi.org/10.1080/09273940590951007
  59. Jonas JB, Spandau UH, Rensch F, Baltz VS, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther. 2007;23(3):240-242. 
  60. Becker HI, Walton RC, Diamant JI, Zegans ME. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol. 2004;122(7):1063-1066. https://doi.org/10.1001/archopht.122.7.1063
  61. Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130(3):287-291.  https://doi.org/10.1016/s0002-9394(00)00491-8
  62. Lopilly Park HY, Kim JH, Lee KM, Park CK. Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloprotei-nases in the conjunctiva and cornea. Exp Eye Res. 2012;94(1):13-21.  https://doi.org/10.1016/j.exer.2011.10.017
  63. Knopf HL. Recurrent uveitis after influenza vaccination. Ann Ophthalmol. 1991;23(6):213-214. 
  64. Wells MB, Garg S. Bilateral panuveitis after influenza vaccination. Retin Cases Brief Rep. 2009;3:386-387. 
  65. Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol. 2010;29(1):26-29.  https://doi.org/10.3109/15569520903427717
  66. Holt HD, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW. Human papilloma virus vaccine associated uveitis. Curr Drug Saf. 2014;9(1):65-68.  https://doi.org/10.2174/15748863113086660062

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.